Chengdong Yu

Chengdong Yu

Auto-generated profile, based on publicly available information

Chengdong Yu

Department of Growth and Development, Capital Institute of Pediatrics, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
CYChengdong Yu
Chengdong Yu
SZShuyuan Zhang
Shuyuan Zhang
HHHuijing He
Huijing He
FWFeitong Wu
Feitong Wu
SLShaoyuan Lei
Shaoyuan Lei
SZShuyang Zhang
Shuyang Zhang
Background: The aim of this study was to investigate the longitudinal associations between the body size trajectory and the cardio-renal-metabolic (CRM) conditions in adulthood, and evaluate the joint association between body size trajectory and polygenic risk scores (PRS) of CRM conditions. Methods: This prospective cohort study included 441 470 UK Biobank participants aged 40 to 70 years, recruited between March 2006 and July 2010. CRM conditions were defined as the occurrence of any of cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes (T2D). Cox regression models and Fine-Gray sub-distribution hazard models were used to estimate associations and competing risks of mortality. Mediation analysis and group-based trajectory modeling were performed to assess mediation effects and body size change trajectories. Additionally, interaction analyses were conducted to examine the combined effects of between the body size trajectories and PRS on CRM conditions. Results: The incidence density of CRM conditions was 128.9 per 1000 person-years. Adulthood overweight/obesity mediated the association between childhood plumper body size and CRM conditions (mediation proportion = 55.82%, P < 0.0001). Five trajectories of body size from birth to adulthood were identified, and the other four trajectories differing from the “normal-average-normal” trajectory were associated with increased risks of CRM conditions, with hazard ratio (HR) and 95% confidence interval (CI) ranging from 1.20 (1.15, 1.26) to 1.32 (1.28, 1.37). Intermediate and high genetic risk groups demonstrated elevated risks of CVD, CKD, and T2D, and the additive interactions were found between body size trajectories and PRS on CKD and T2D. Conclusions: Maintaining a normal body size across the life cycle, even with intermediate or high genetic risk, may help mitigate the impact of genetic risk. Early monitoring and interventions aimed at sustaining a normal body size throughout life could provide life-course benefits in preventing CRM conditions, particularly for individuals with elevated genetic risk. Graphical JOURNAL/ijos/04.03/01279778-202508000-00020/figure1/v/2026-10-30T033856Z/r/image-jpeg

1 January 2022 in Global Transitions
Verified
Journal Article
Open access
HHHuijing He
Huijing He
LPLi Pan
Li Pan
YHYaoda Hu
Yaoda Hu
JTJi Tu
Ji Tu
CYChengdong Yu
Chengdong Yu
GSGuangliang Shan
Guangliang Shan